Cergentis is a genomics-focused biotechnology company and a leading provider of genetic quality control solutions. They specialize in delivering innovative solutions to ensure the genetic quality of future therapies. With their proprietary Targeted Locus Amplification (TLA) technology platform, they enable the targeted complete Next Generation Sequencing of any genomic locus in any genome of interest.

Cergentis supports leading pharmaceutical companies and research institutes in the characterization and quality control of their genetically engineered models, biopharmaceutical cell line development, and cell and gene therapy products. By providing objective genomic evidence to regulators and supporting patient safety, they help de-risk R&D program decisions, minimize time-to-clinic, and contribute to the success of biopharmaceutical medicine programs worldwide. Founded in 2012 as a spin-off from the Hubrecht Institute for Development Biology & Stem Cell Research and the Royal Netherlands Academy of Arts and Sciences (KNAW), Cergentis became part of Solvias in July 2022.

Their TLA-based genetic QC solutions have been widely published and recognized, with more than 60 peer-reviewed papers showcasing their expertise. Visit their website for more information and to explore their range of products and services